Your shopping cart is currently empty

DPMI-ω is a dual-specific D-peptide antagonist of the carcinogenic proteins MDM2 and MDMX. When loaded onto gold nanoparticles, DPMI-ω effectively penetrates tumor cells and kills them by reactivating the p53 signaling pathway. It disrupts the p53-MDM2/MDMX complex and inhibits the growth of B16 melanoma while inducing G0/G1 phase cell cycle arrest. Combined with anti-PD1 antibodies, DPMI-ω enhances immunotherapy by amplifying CD3+/CD8+ cytotoxic T cells and inhibiting CD4+/CD25+ regulatory T cells. DPMI-ω is applicable in melanoma research.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | DPMI-ω is a dual-specific D-peptide antagonist of the carcinogenic proteins MDM2 and MDMX. When loaded onto gold nanoparticles, DPMI-ω effectively penetrates tumor cells and kills them by reactivating the p53 signaling pathway. It disrupts the p53-MDM2/MDMX complex and inhibits the growth of B16 melanoma while inducing G0/G1 phase cell cycle arrest. Combined with anti-PD1 antibodies, DPMI-ω enhances immunotherapy by amplifying CD3+/CD8+ cytotoxic T cells and inhibiting CD4+/CD25+ regulatory T cells. DPMI-ω is applicable in melanoma research. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.